---
title: "Capital pours into innovative drugs. The Stock Connect (for Hong Kong) innovative drug ETF E Fund (159316) has attracted over 20 billion yuan in the past 6 months."
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/39738464.md"
description: "On April 7th, the Hong Kong Stock Exchange remained closed due to the Easter holiday. As of April 2nd, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) has risen 37.23% in the past year. The E Fund Stock Connect Innovative Drug ETF (159316) tracks the Hang Seng Stock Connect Innovative Drug Index and continues to see capital inflows. As of the previous trading day, the fund had a net inflow of 150 million yuan over the past three months, 2.05 billion yuan over the past six months, and 4.592 billion yuan over the past year. With the intensive disclosure of listed companies' 2025 annual reports..."
datetime: "2026-04-07T06:49:08.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39738464.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39738464.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39738464.md)
author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)"
---

# Capital pours into innovative drugs. The Stock Connect (for Hong Kong) innovative drug ETF E Fund (159316) has attracted over 20 billion yuan in the past 6 months.

On April 7th, the Hong Kong Stock Exchange remained closed due to the Easter holiday. As of April 2nd, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) has risen 37.23% in the past year.

The E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) tracks the Hang Seng Stock Connect Innovative Drug Index and continues to see significant capital inflows. As of the previous trading day, the fund recorded a net inflow of 150 million yuan over the past three months, 2.05 billion yuan over the past six months, and 4.592 billion yuan over the past year.

With the intensive disclosure of listed companies' 2025 annual reports, the report cards of China's innovative drug companies have also emerged. Data shows that in 2025, the overall revenue of Hong Kong-listed 18A biotech companies exceeded 96.5 billion yuan. Including companies like Hengrui Medicine and Hansoh Pharma, the total annual revenue surpassed the 100 billion yuan mark.

The commercialization capabilities of leading companies have significantly strengthened, with BeiGene and Innovent Biologics both achieving annual revenues exceeding 10 billion yuan. Meanwhile, China has become a core supplier of high-quality innovative drug pipelines globally, and out-licensing (BD) transactions are advancing rapidly. The latest data from the National Medical Products Administration shows that in the first quarter of 2026 alone, the total value of China's innovative drug out-licensing deals has already exceeded $60 billion, a figure close to half of the total for the entire year of 2025.

Huayuan Securities pointed out that multinational pharmaceutical companies and overseas PE institutions are paying increasing attention to Chinese assets, with a significantly stronger willingness to cooperate, indicating that the international recognition and supply quality of China's innovative drugs have improved.

Zhongtai Securities stated that the performance of leading companies has initially verified the recovery trend of the sector. At the same time, with key clinical data readouts from AACR 2026 and ASCO 2026 imminent, the overseas expansion of domestic innovative drugs is accelerating from a "follow-on" stage towards global leadership.

The management fee rate for the E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) is 0.15%, the custody fee rate is 0.05%, and the total expense ratio is 0.2%. The relatively low fees can effectively reduce costs for investors.

The E Fund Hong Kong Stock Connect Innovative Drug ETF (159316) is currently the only ETF product in the market tracking the Hang Seng Innovative Drug Index, offering high elasticity and scarcity, helping investors better capture the current investment opportunities in Hong Kong-listed innovative drug stocks.

Related Products:

E Fund Hong Kong Stock Connect Innovative Drug ETF (159316)

E Fund Hang Seng Stock Connect Innovative Drug Link A (024328)

E Fund Hang Seng Stock Connect Innovative Drug Link C (024329)

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)